Skip to main content

Advertisement

Table 1 Patient and tumour characteristics

From: Proteomic biomarkers predicting lymph node involvement in serum of cervical cancer patients. Limitations of SELDI-TOF MS

  Numerical display LN positive (n = 12) LN negative (n = 48) Test P value
Age in years Mean (95%CI) 45.8 (38.5–53.0) 46.7 (43.3–50.0) T-test 0.732
FIGO stage
 Ia2 n (%) 0 (0.0) 2 (4.2) χ 2 0.134
 Ib1 n (%) 6 (50.0) 37 (77.1)   
 Ib2 n (%) 2 (16.7) 2 (4.2)   
 IIa n (%) 4 (33.3) 7 (14.6)   
Histological subtype
 Squamous cell carcinoma n (%) 11 (91.7) 29 (60.4) χ 2 0.119
 Adenocarcinoma n (%) 1 (8.3) 17 (35.4)   
 Adenosquamous carcinoma n (%) 0 (0.0) 2 (4.2)   
Lymph nodes
 Number of positive LN Median (min-max) 1 (1–7) 0 (0–0) Mann–Whitney <0.001
 Number of removed LN Median (min-max) 28 (4–50) 34 (18–89) Mann–Whitney 0.241
LVSI
 Positive n (%) 10 (83.3) 16 (33.3) χ 2 0.005
 Negative n (%) 2 (16.7) 32 (66.7)   
Follow-up
 Follow-up (in months) Mean (95%CI) 61.8 (42.0–81.5) 61.7 (49.0–66.5) T-test 0.997
Recurrence
 Recurrence n (%) 3 (25.0) 7 (14.6) χ 2 0.665
 No recurrence n (%) 9 (75.0) 41 (85.4)   
  1. Abbreviations: LN = lymph node; FIGO = International Federation of Gynecology and Obstetrics; LVSI = lymphvascular space involvement.